Source-grounded facts extracted from Theriva Biologics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Theriva Biologics, Inc. reported financial results for quarter ended March 31, 2026.
“On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.”
Theriva Biologics, Inc. reported financial results for the full year ended December 31, 2025.
“Rockville, MD, March 12, 2026 – TherivaTM Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.”
Theriva Biologics, Inc. entered into Agreement with Rasayana Therapeutics, Inc. valued at $300,000 (effective 2026-02-18).
“On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Rasayana Therapeutics, Inc. (“Rasayana”)”
Theriva Biologics, Inc. issued 16,184,560 shares of Common Stock of warrant to certain holders of existing warrants for cash exercise of existing warrants at $0.54 per share for aggregate gross proceeds of approximately $4.4 million.
“Warrants, the “Existing Warrants”). Pursuant to the Inducement Agreement, (1) the Holders agreed to exercise for cash the Existing Warrants at a reduced exercise price of $0.54 per share and (2) the Company agreed to issue to the Holders new Common Stock Purchase Warrants to purchase up to an aggregate of 16,184,560 shares of Common Stock (the “New”
Theriva Biologics, Inc. announced a restructuring with charges of approximately $520,000 affecting global Company workforce (approximately seven employees or 32% of the current global Company workforce).
“its best opportunity for success. The Company expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately $520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025. These charges consist primarily of cash severance and”
Theriva Biologics, Inc.: increased authorized shares of common stock from 14,000,000 to 350,000,000 (effective 2024-11-01).
“On November 1, 2024, the Company filed a Certificate of Change to its Articles of Incorporation with the Secretary of State of the State of Nevada (the “Certificate of Change”) that was effective on such date that increased the number of the Company’s authorized shares of common stock, $0.001 par value per share from 14,000,000 shares to $350,000,000 shares.”
Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.”
Theriva Biologics, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 13, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2023.”
Theriva Biologics, Inc. shareholders approved Ratification of the appointment of BDO USA P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-10-02 meeting.
“Proposal 2 — Ratification of the appointment of BDO USA P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The stockholders ratified and approved the appointment”
Theriva Biologics, Inc. shareholders approved Election of Directors at the 2023-10-02 meeting.
“Proposal 1 — Election of Directors . The following four (4) individuals were elected as directors”
Theriva Biologics, Inc.: Amended and restated bylaws to add advance notice procedures for director nominations and stockholder proposals (effective 2023-10-03).
“On August 9, 2023, the Board of Directors (the “Board”) of Theriva Biologics, Inc., a Nevada corporation (the “Company”) amended and restated the Company’s amended and restated bylaws (the “Bylaws”), effective October 3, 2023. The Bylaws include new provisions related to advance notice procedures.”
Theriva Biologics, Inc. reported financial results for second quarter ended June 30, 2023.
“On August 8, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended June 30, 2023.”
Theriva Biologics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“On March 30, 2023, Theriva Biologics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.”
Theriva Biologics, Inc. entered into Share Repurchase Agreement with Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar valued at $288,072 (effective 2022-12-20).
“On December 22, 2022, Theriva Biologics, Inc. (the “Company”) repurchased an aggregate of 720,000 shares of its common stock, par value $0.0001 (the “Common Stock”) from Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar (the “Selling Stockholders”), three founders of its subsidiary Theriva Biosciences S.L. (formerly known as VCN Biosciences S.L.) in a privately negotiated transaction pursuant to the terms of a Share Repurchase Agreement entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) entered into on December 20, 2022 with each of the Selling Stockholders. The price per share was $0.4001, which was the closing price of the Common Stock on the day prior to the closing for an aggregate purchase price was $288,072.”
Theriva Biologics, Inc. reported financial results for for the quarter ended September 30, 2022.
“On November 10, 2022, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.